Thermo Fisher Scientific Inc. TMO
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/31/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.35B | 46.34B | 45.20B | 44.56B | 43.74B |
| Total Other Revenue | 0.00 | 0.00 | 1.00M | 1.00M | 1.00M |
| Total Revenue | 47.35B | 46.34B | 45.20B | 44.56B | 43.74B |
| Cost of Revenue | 27.81B | 27.35B | 26.70B | 26.25B | 25.63B |
| Gross Profit | 19.54B | 18.99B | 18.50B | 18.30B | 18.10B |
| SG&A Expenses | 9.01B | 8.77B | 8.59B | 8.52B | 8.46B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -134.00M | -134.00M | -134.00M | -135.00M | 30.00M |
| Total Operating Expenses | 38.10B | 37.38B | 36.55B | 36.03B | 35.54B |
| Operating Income | 9.26B | 8.95B | 8.65B | 8.52B | 8.20B |
| Income Before Tax | 7.84B | 7.59B | 7.39B | 7.27B | 7.12B |
| Income Tax Expenses | 742.00M | 597.00M | 522.00M | 547.00M | 544.00M |
| Earnings from Continuing Operations | 7.09K | 6.99K | 6.87K | 6.72K | 6.58K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -22.00M | -21.00M | -18.00M | -17.00M | -5.00M |
| Net Income | 7.07B | 6.97B | 6.85B | 6.70B | 6.57B |
| EBIT | 9.26B | 8.95B | 8.65B | 8.52B | 8.20B |
| EBITDA | 12.36B | 11.90B | 11.46B | 11.30B | 10.99B |
| EPS Basic | 18.99 | 18.62 | 18.21 | 17.76 | 17.33 |
| Normalized Basic EPS | 14.36 | 13.88 | 13.46 | 13.24 | 12.81 |
| EPS Diluted | 18.94 | 18.57 | 18.17 | 17.72 | 17.31 |
| Normalized Diluted EPS | 14.33 | 13.86 | 13.44 | 13.22 | 12.80 |
| Average Basic Shares Outstanding | 1.49B | 1.50B | 1.50B | 1.51B | 1.52B |
| Average Diluted Shares Outstanding | 1.49B | 1.50B | 1.51B | 1.51B | 1.52B |
| Dividend Per Share | 1.84 | 1.80 | 1.76 | 1.72 | 1.68 |
| Payout Ratio | 9.52% | 9.50% | 9.48% | 9.49% | 9.48% |